552

FITC-conjugated Goat Anti-Human Apolipoprotein AII | ABMC-F04

(No reviews yet) Write a Review
SKU:
552-F04-GEN
Availability:
IN STOCK
£700.00

Description

FITC-conjugated Goat Anti-Human Apolipoprotein AII |F04

Host Species: Goat
Concentration: 1 mg/ml (OD 1.35 / 280 nm)
Antigen: Human Apolipoprotein AII
Purification: Affinity purified
Form: Freeze dried powder
Buffer: 75 mM Sodium Phosphate, 75 mM NaCl, 0.5 mM EDTA, 0.02% NaN3, pH 7.2
Specificity

Specifically binds to human apo AI. Molar F/P ratio is 4.7. The investigator should determine working dilutions.

Use: The antibody can be used for detection of apo AII in plasma and lipoproteins, immunoassays, immunoblots, enzyme conjugation, or biotinylation.
Storage: -20°C for long-term storage, 4°C for short- term storage. Aliquot to avoid repeated freezing and thawing.
Form: Freeze dried powder
Stabilizer: 5 mg / ml Bovine Serum Albumin.

Reconstitution

and Storage:

Freeze-dried product should be stored refrigerated until opened. After opening, restore to suggested ml volume with distilled water. If it is not completely clear after standing for 1-2 hours at room temperature, centrifuge the product. It is stable for several weeks at 4°C as an undiluted liquid. Do not use for more than one day after dilution. For extended storage after reconstitution, we suggest aliquot to avoid repeated freezing and thawing; or the addition of an equal volume of glycerol to make a final glycerol concentration of 50%, followed by storage at -20°C. The concentration of protein and buffer salts will decrease to one-half of the original after the addition of glycerol.

 


*These products are for research or manufacturing use only, not for use in human therapeutic or diagnostic applications.

IMPORTANCE

Apo AII comprises 25% of HDL. It exists in human plasma as a dimer of 2 identical chains of 77 amino acid residues, joined by disulfide. The molecular weight is reported to be 8.7 kDa for a single chain (Brewer et al., 1972).

Studies on mouse reported that apo AII may be proatherogenic (Warden et al., 1993); however, case-control study in the large European Prospective Investigation demonstrated that plasma Apo AII concentrations were strongly inversely correlated with CHD events (Birjmohun et al., 2007).

View AllClose

Additional Information

Size:
0.5 ml
View AllClose